SCHEMBL2274172

SCHEMBL2274172

O=C(O)c1cccc[n+]1[O-].[Zn]

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
SLC2A1 P11166 1/20 0.42
LMNA P02545 3/20 0.40
HTT P42858 1/20 0.40
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 3/20 0.38
MAPT P10636 2/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
DAO P14920 1/20 0.37
TSHR P16473 1/20 0.37
NAPRT Q6XQN6 1/20 0.37
ALOX15 P16050 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.34
PTPN1 P18031 1/20 0.33
ERCC5 P28715 1/20 0.33
FEN1 P39748 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1489277 0.98 KDM4E (0.44) KDM4ETDP1SLC2A1LMNAHTT
SCHEMBL29475148 0.98 KDM4E (0.44) KDM4ETDP1SLC2A1LMNAHTT
SCHEMBL10633313 0.79 ALDH1A1 (0.50) KDM4ETDP1SLC2A1LMNAKMT2A
SCHEMBL2833136 0.78 KDM4E (0.43) KDM4ETDP1SLC2A1LMNAHTT
Zinc Ion SCHEMBL9440226 0.78 KDM4E (0.43) KDM4ETDP1SLC2A1LMNAHTT
SCHEMBL30488814 0.78 KDM4E (0.43) KDM4ETDP1SLC2A1LMNAHTT
SCHEMBL4833163 0.78 TDP1 (0.43) KDM4ETDP1SLC2A1LMNAHTT
SCHEMBL30040657 0.76 LMNA (0.41) KDM4ETDP1SLC2A1LMNAHTT
SCHEMBL9682539 0.75 KDM4E (0.41) KDM4ETDP1SLC2A1LMNAHTT
SCHEMBL2026022 0.74 TSHR (0.45) KDM4ETDP1SLC2A1LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0433457-B1 ANTIPRURITIC COMPOSITION SHISEIDO CO LTD (JP) 1994-10-19 EP claimed
EP-0433457-A1 ANTIPRURITIC COMPOSITION SHISEIDO COMPANY LIMITED (JP) 1991-06-26 EP claimed
US-8003688-B2 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract IMMUPHARM APS (DK) 2011-08-23 US disclosed
US-7671086-B2 Pharmaceutical compositions comprising flavonoids and menthol IMMUPHARM A/S (DK) 2010-03-02 US disclosed
US-20090227670-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING FLAVONOIDS AND MENTHOL IMMUPHARM A/S (DK) 2009-09-10 US disclosed
US-7585890-B2 Pharmaceutical compositions comprising flavonoids and menthol IMMUNPHARM A/S (DK) 2009-09-08 US disclosed
EP-2089422-A1 METHODS OF SEPARATING NUCLEIC ACIDS AND PROTEIN Natimmune A/S (DK) 2009-08-19 EP disclosed
WO-2008106979-A2 PHARMACEUTICAL COMPOSITIONS COMPRISING FLAVONOIDS AND XYLITOL IMMUPHARM A/S (DK) 2008-09-12 WO disclosed
WO-2008064686-A1 METHODS OF SEPARATING NUCLEIC ACIDS AND PROTEIN NATIMMUNE A/S (DK) 2008-06-05 WO disclosed
EP-1556021-B1 PHARMACEUTICAL COMPOSITIONS COMPRISING FLAVONOIDS AND MENTHOL IMMUPHARM AS (DK) 2007-12-19 EP disclosed
US-7166640-B2 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract IMMUPHARM APS (DK) 2007-01-23 US disclosed
EP-1307189-B1 USE OF HYDROXYETHYLRUTOSIDES FOR TREATING SYMPTOMS OF COMMON COLD, ALLERGIC RHINITIS AND INFECTIONS RELATING TO THE RESPIRATORY TRACT IMMUPHARM APS (DK) 2006-05-10 EP disclosed
CN-1717227-A Pharmaceutical compositions comprising flavonoids and menthol IMMUPHARM AS (DK) 2006-01-04 CN disclosed
US-20050245467-A1 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract IMMUPHARM APS (DK) 2005-11-03 US disclosed
EP-1556021-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING FLAVONOIDS AND MENTHOL Immupharm A/S (DK) 2005-07-27 EP disclosed
WO-2004037237-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING FLAVONOIDS AND MENTHOL IMMUPHARM A/S (DK) 2004-05-06 WO disclosed
US-20040053858-A1 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract IMMUPHARM APS (DK) 2004-03-18 US disclosed
EP-0433457-B1 ANTIPRURITIC COMPOSITION SHISEIDO CO LTD (JP) 1994-10-19 EP disclosed
US-5219847-A Antipruritic composition SHISEIDO COMPANY, LTD. (JP) 1993-06-15 US disclosed
EP-0433457-A1 ANTIPRURITIC COMPOSITION SHISEIDO COMPANY LIMITED (JP) 1991-06-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245467-A1 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract CMA1, CHIA, C1QBP KDM4E 4189/4885TDP1 4320/4885SLC2A1 2962/4885
US-20040053858-A1 Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract CMA1, CHIA, C1QBP KDM4E 4189/4885TDP1 4320/4885SLC2A1 2962/4885
US-20090227670-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING FLAVONOIDS AND MENTHOL CHIA, MAVS, C1QBP KDM4E 430/4885TDP1 2444/4885SLC2A1 4710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.